Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Merck's Miransertib Mesylate?
Miransertib Mesylate is a small molecule commercialized by Merck, with a leading Phase I program in Ovarian Cancer;Endometrial Cancer. According...
Data Insights
Risk adjusted net present value: What is the current valuation of Merck's Miransertib Mesylate?
Miransertib Mesylate is a small molecule commercialized by Merck, with a leading Phase I program in Lymphoma. According to Globaldata,...